BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kwong AJ, Wall A, Melcher M, Wang U, Ahmed A, Subramanian A, Kwo PY. Liver transplantation for hepatitis C virus (HCV) non-viremic recipients with HCV viremic donors. Am J Transplant. 2019;19:1380-1387. [PMID: 30378723 DOI: 10.1111/ajt.15162] [Cited by in Crossref: 66] [Cited by in F6Publishing: 61] [Article Influence: 16.5] [Reference Citation Analysis]
Number Citing Articles
1 Prakash K, Aslam S. New updates in the world of hepatitis C virus infected organ transplantation. Curr Opin Organ Transplant 2020;25:364-70. [PMID: 32520787 DOI: 10.1097/MOT.0000000000000785] [Reference Citation Analysis]
2 Terrault NA, Sher L. Expanding the use of hepatitis C–positive donors and keeping recipient safety at the forefront. Am J Transplant 2019;20:627-8. [DOI: 10.1111/ajt.15745] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Terrault NA, Burton J, Ghobrial M, Verna E, Bayer J, Klein C, Victor D, Mohan S, Trotter J, Dodge J, Niemann CU, Rubin RA. Prospective Multicenter Study of Early Antiviral Therapy in Liver and Kidney Transplant Recipients of HCV-Viremic Donors. Hepatology 2021;73:2110-23. [PMID: 32926749 DOI: 10.1002/hep.31551] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
4 Yu M, Chen P, Dai C, Hu T, Huang C, Huang Y, Hung C, Lin C, Liu C, Liu C, Peng C, Lin H, Kao J, Chuang W. 2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations. Journal of the Formosan Medical Association 2020;119:1135-57. [DOI: 10.1016/j.jfma.2020.04.002] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 12.0] [Reference Citation Analysis]
5 Couri T, Aronsohn A. When Theory Becomes Reality: Navigating the Ethics of Transplanting Hepatitis C Virus-Positive Livers Into Negative Recipients. Clin Liver Dis (Hoboken) 2019;14:131-4. [PMID: 31709040 DOI: 10.1002/cld.849] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
6 Stewart ZA, Shah SA, Rolls JA, Guarrera JV, Kandaswamy R, Axelrod DA. Best practice recommendations for the use of hepatitis C viremic donor organs for hepatitis C virus naïve recipients. Clin Transplant 2021;:e14381. [PMID: 34086371 DOI: 10.1111/ctr.14381] [Reference Citation Analysis]
7 Massoud O. Hepatitis C: looking into the future. Expert Rev Gastroenterol Hepatol 2020;14:367-74. [PMID: 32216467 DOI: 10.1080/17474124.2020.1746641] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
8 Murag S, Dennis BB, Kim D, Ahmed A, Cholankeril G. Recent advances in liver transplantation with HCV seropositive donors. F1000Res 2019;8:F1000 Faculty Rev-2151. [PMID: 31942236 DOI: 10.12688/f1000research.20387.1] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Logan C, Yumul I, Cepeda J, Pretorius V, Adler E, Aslam S, Martin NK. Cost-effectiveness of using hepatitis C viremic hearts for transplantation into HCV-negative recipients. Am J Transplant 2021;21:657-68. [PMID: 32777173 DOI: 10.1111/ajt.16245] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Ohira M, Tanimine N, Kobayashi T, Ohdan H. Essential updates 2018/2019: Liver transplantation. Ann Gastroenterol Surg 2020;4:195-207. [PMID: 32490333 DOI: 10.1002/ags3.12321] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Weinfurtner K, Reddy KR. Hepatitis C viraemic organs in solid organ transplantation. J Hepatol. 2021;74:716-733. [PMID: 33212088 DOI: 10.1016/j.jhep.2020.11.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Woelfel I, Gupta A, Renshaw S, Poulose B. Length of stay and surgical site complications are not increased after elective incisional hernia in patients with a history of solid organ transplantation. Surg Endosc 2021. [PMID: 33788030 DOI: 10.1007/s00464-021-08458-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Liyanage L, Muzaale AD, Henderson ML, Durand CM. Living kidney donation in individuals with hepatitis C and HIV infection: rationale and emerging evidence. Curr Transplant Rep 2019;6:167-76. [PMID: 32855901 DOI: 10.1007/s40472-019-00242-5] [Reference Citation Analysis]
14 Delman AM, Ammann AM, Shah SA. The current status of virus-positive liver transplantation. Curr Opin Organ Transplant 2021;26:160-7. [PMID: 33595981 DOI: 10.1097/MOT.0000000000000850] [Reference Citation Analysis]
15 Dahlqvist G, Moreno C, Starkel P, Detry O, Coubeau L, Jochmans I. Innovations in liver transplantation in 2020, position of the Belgian Liver Intestine Advisory Committee (BeLIAC). Acta Gastroenterol Belg 2021;84:347-59. [PMID: 34217187 DOI: 10.51821/84.2.347] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Gernhofer YK, Brambatti M, Greenberg BH, Adler E, Aslam S, Pretorius V. The impact of using hepatitis c virus nucleic acid test-positive donor hearts on heart transplant waitlist time and transplant rate. J Heart Lung Transplant 2019;38:1178-88. [PMID: 31492607 DOI: 10.1016/j.healun.2019.08.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
17 Verna EC, Tsapepas D, Emond JC, Brown RS, Mohan S. Utilization of Hepatitis C Virus (HCV)‐Viremic Organs for HCV Negative Recipients: Is Practice Speeding Past the Evidence? Hepatology 2020;71:4-7. [DOI: 10.1002/hep.30933] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
18 Aslam S, Yumul I, Mariski M, Pretorius V, Adler E. Outcomes of heart transplantation from hepatitis C virus–positive donors. The Journal of Heart and Lung Transplantation 2019;38:1259-67. [DOI: 10.1016/j.healun.2019.08.019] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]
19 Cannon RM, Goldberg DS, Eckhoff DE, Anderson DJ, Orandi BJ, Locke JE. Early Outcomes With the Liver-kidney Safety Net. Transplantation 2021;105:1261-72. [PMID: 33741848 DOI: 10.1097/TP.0000000000003365] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Bethea E, Arvind A, Gustafson J, Andersson K, Pratt D, Bhan I, Thiim M, Corey K, Bloom P, Markmann J, Yeh H, Elias N, Kimura S, Dageforde LA, Cuenca A, Kawai T, Safa K, Williams W, Gilligan H, Sise M, Fishman J, Kotton C, Kim A, Rogers CC, Shao S, Cote M, Irwin L, Myoung P, Chung RT. Immediate administration of antiviral therapy after transplantation of hepatitis C-infected livers into uninfected recipients: Implications for therapeutic planning. Am J Transplant. 2020;20:1619-1628. [PMID: 31887236 DOI: 10.1111/ajt.15768] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
21 Durand CM, Chattergoon MA. Bypassing the bottleneck: intentional hepatitis C transmission with organ transplant. J Clin Invest 2019;129:3038-40. [PMID: 31232703 DOI: 10.1172/JCI129982] [Reference Citation Analysis]
22 Nair SP, Marella HK, Maliakkal B, Snyder H, Handley C, Kothadia JP, Ali B, Satapathy SK, Molnar MZ, Clark I, Jain R, Helmick R, Eymard C, Eason JD. Transplantation of liver from hepatitis C-infected donors to hepatitis C RNA-negative recipients: Histological and virologic outcome. Clin Transplant 2021;35:e14281. [PMID: 33690929 DOI: 10.1111/ctr.14281] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Nangia G, Borges K, Reddy KR. Use of HCV‐infected organs in solid organ transplantation: An ethical challenge but plausible option. J Viral Hepat 2019;26:1362-71. [DOI: 10.1111/jvh.13130] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
24 Anwar N, Kaiser TE, Bari K, Schoech M, Diwan TS, Cuffy MC, Silski L, Quillin RC, Safdar K, Shah SA. Use of Hepatitis C Nucleic Acid Test–Positive Liver Allografts in Hepatitis C Virus Seronegative Recipients. Liver Transpl 2020;26:673-80. [DOI: 10.1002/lt.25741] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
25 Kappus MR, Wolfe CR, Muir AJ. Direct-Acting Antivirals and Organ Transplantation: Is There Anything We Can't Do? J Infect Dis. 2020;222:S794-S801. [PMID: 33245347 DOI: 10.1093/infdis/jiaa420] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
26 Harano T, Haidar G, Schaheen L, Morrell MR, Pilewski JM, D'Cunha J. Successful lung transplantation from a hepatitis C RNA-positive donor to a hepatitis C treatment-experienced recipient with cystic fibrosis. J Thorac Cardiovasc Surg 2019;158:e155-7. [PMID: 31229293 DOI: 10.1016/j.jtcvs.2019.05.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
27 Dunn R, Wetten A, McPherson S, Donnelly MC. Viral hepatitis in 2021: The challenges remaining and how we should tackle them. World J Gastroenterol 2022; 28(1): 76-95 [DOI: 10.3748/wjg.v28.i1.76] [Reference Citation Analysis]
28 Chacon MM, Adams AJ, Kassel CA, Markin NW. High-Risk and Hepatitis C-Positive Organ Donors: Current Practice in Heart, Lung, and Liver Transplantation. J Cardiothorac Vasc Anesth 2020;34:2492-500. [PMID: 31954619 DOI: 10.1053/j.jvca.2019.12.012] [Reference Citation Analysis]
29 Couri T, Aronsohn A. You Can't Have One Without the Other: Innovation and Ethical Dilemmas in Gastroenterology and Hepatology. Clin Gastroenterol Hepatol 2021;19:2015-9. [PMID: 32445954 DOI: 10.1016/j.cgh.2020.05.024] [Reference Citation Analysis]
30 Torabi J, Rocca JP, Ajaimy M, Melvin J, Campbell A, Akalin E, Liriano LE, Azzi Y, Pynadath C, Greenstein SM, Le M, Goldstein DY, Fox AS, Carrero J, Weiss JM, Powell T, Racine AD, Reinus JF, Kinkhabwala MM, Graham JA. Commercial insurance delays direct-acting antiviral treatment for hepatitis C kidney transplantation into uninfected recipients. Transpl Infect Dis. 2021;23:e13449. [PMID: 32810315 DOI: 10.1111/tid.13449] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
31 Crismale JF, Ahmad J. Expanding the donor pool: Hepatitis C, hepatitis B and human immunodeficiency virus-positive donors in liver transplantation. World J Gastroenterol 2019; 25(47): 6799-6812 [PMID: 31885421 DOI: 10.3748/wjg.v25.i47.6799] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
32 Ghany MG, Morgan TR;  AASLD-IDSA Hepatitis C Guidance Panel. Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology. 2020;71:686-721. [PMID: 31816111 DOI: 10.1002/hep.31060] [Cited by in Crossref: 145] [Cited by in F6Publishing: 133] [Article Influence: 72.5] [Reference Citation Analysis]
33 Kapila N, Al-Khalloufi K, Bejarano PA, Vanatta JM, Zervos XB. Fibrosing cholestatic hepatitis after kidney transplantation from HCV-viremic donors to HCV-negative recipients: A unique complication in the DAA era. Am J Transplant. 2020;20:600-605. [PMID: 31448549 DOI: 10.1111/ajt.15583] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
34 Crismale JF, Khalid M, Bhansali A, De Boccardo G, Khaim R, Florman SS, Shapiro R, Schiano TD. Liver, simultaneous liver-kidney, and kidney transplantation from hepatitis C-positive donors in hepatitis C-negative recipients: A single-center study. Clin Transplant 2020;34:e13761. [PMID: 31808193 DOI: 10.1111/ctr.13761] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
35 Martin EF. Paradigm Shift in Utilization of Livers from Hepatitis C-Viremic Donors into Hepatitis C Virus-Negative Patients. Clin Liver Dis 2021;25:195-207. [PMID: 33978579 DOI: 10.1016/j.cld.2020.08.009] [Reference Citation Analysis]
36 Aqel B, Wijarnpreecha K, Pungpapong S, Taner CB, Reddy K, Leise M, Mi L, Dickson RC. Outcomes following liver transplantation from HCV-seropositive donors to HCV-seronegative recipients. Journal of Hepatology 2021;74:873-80. [DOI: 10.1016/j.jhep.2020.11.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
37 Nnani DU, Campbell A, Ajaimy M, Saeed O, Patel SR, Ahmed S, Graham JA, Jorde UP. Effect of glecaprevir/pibrentasvir on weight-adjusted tacrolimus trough/dose ratios in heart and kidney transplant recipients. Transpl Infect Dis 2021;23:e13716. [PMID: 34407270 DOI: 10.1111/tid.13716] [Reference Citation Analysis]
38 Kahn JA. The use of organs from hepatitis C virus-viremic donors into uninfected recipients. Curr Opin Organ Transplant. 2020;25:620-625. [PMID: 33105203 DOI: 10.1097/mot.0000000000000826] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
39 Moayedi Y, Gulamhusein AF, Khush KK. Treading lightly as we step into a new era: Use of hepatitis C virus-infected organs for transplantation. J Thorac Cardiovasc Surg 2020;159:505-10. [PMID: 31587888 DOI: 10.1016/j.jtcvs.2019.05.091] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
40 Leung DH, Squires JE, Jhaveri R, Kerkar N, Lin CH, Mohan P, Murray KF, Gonzalez-Peralta RP, Roberts EA, Sundaram SS. Hepatitis C in 2020: A North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Position Paper. J Pediatr Gastroenterol Nutr. 2020;71:407-417. [PMID: 32826718 DOI: 10.1097/mpg.0000000000002814] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
41 Zahid MN, Wang S, Learn GH, Abt PL, Blumberg EA, Reese PP, Goldberg DS, Shaw GM, Bar KJ. High multiplicity infection following transplantation of hepatitis C virus-positive organs. J Clin Invest 2019;129:3134-9. [PMID: 31112523 DOI: 10.1172/JCI127203] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
42 Danford CJ, Curry MP. Over 2 Decades of Transplanting Hepatitis C Virus-Positive Liver Allografts: Almost Full Circle With Encouraging Early Results. Liver Transpl 2020;26:626-7. [PMID: 32173967 DOI: 10.1002/lt.25754] [Reference Citation Analysis]
43 Pérez IB, Duca A. Top Papers in Liver Transplantation 2017-2018. Transplant Proc 2021;53:620-3. [PMID: 32247594 DOI: 10.1016/j.transproceed.2020.01.085] [Reference Citation Analysis]
44 Prakash K, Ramirez-Sanchez C, Ramirez SI, Logan C, Law N, Mekeel K, Pretorius V, Aslam S. Post-transplant survey to assess patient experiences with donor-derived HCV infection. Transpl Infect Dis 2020;22:e13402. [PMID: 32634289 DOI: 10.1111/tid.13402] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
45 Stewart ZA, Stern J, Ali NM, Kalia HS, Khalil K, Jonchhe S, Weldon EP, Dieter RA, Lewis TC, Funches N, Crosby S, Seow M, Berger JC, Dagher NN, Gelb BE, Watkins AC, Moazami N, Smith DE, Kon ZN, Chang SH, Reyentovich A, Angel LF, Montgomery RA, Lonze BE. Clinical and Financial Implications of 2 Treatment Strategies for Donor-derived Hepatitis C Infections. Transplant Direct 2021;7:e762. [PMID: 34514117 DOI: 10.1097/TXD.0000000000001222] [Reference Citation Analysis]
46 Burra P, Samuel D, Sundaram V, Duvoux C, Petrowsky H, Terrault N, Jalan R. Limitations of current liver donor allocation systems and the impact of newer indications for liver transplantation. J Hepatol 2021;75 Suppl 1:S178-90. [PMID: 34039488 DOI: 10.1016/j.jhep.2021.01.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
47 Morales JM, Sawinski D. New insights into the rational use of HCV+ organs worldwide. Clin Transplant 2019;33:e13739. [PMID: 31648391 DOI: 10.1111/ctr.13739] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
48 Raasikh T, Jamali T, Flores A, Cotton RT, Ramanathan V, Tan HP, Hernaez R. Systematic review: hepatitis C viraemic allografts to hepatitis C-negative recipients in solid organ transplantation. Aliment Pharmacol Ther 2021;54:571-82. [PMID: 34265111 DOI: 10.1111/apt.16508] [Reference Citation Analysis]
49 Hudson MR, Webb AR, Logan AT, Silverman A, Brueckner AJ. Outcomes of hepatitis C virus nucleic acid testing positive donors in aviremic recipients with delayed direct-acting antiviral initiation. Clin Transplant 2021;:e14386. [PMID: 34132438 DOI: 10.1111/ctr.14386] [Reference Citation Analysis]
50 Zhang W, Aryan M, Qian S, Cabrera R, Liu X. A Focused Review on Recent Advances in the Diagnosis and Treatment of Viral Hepatitis. Gastroenterology Res 2021;14:139-56. [PMID: 34267829 DOI: 10.14740/gr1405] [Reference Citation Analysis]
51 Graham JA, Torabi J, Ajaimy M, Akalin E, Liriano LE, Azzi Y, Pynadath C, Greenstein SM, Goldstein DY, Fox AS, Weiss JM, Powell TP, Reinus JF, Kinkhabwala MM, Rocca JP. Transplantation of viral-positive hepatitis C-positive kidneys into uninfected recipients offers an opportunity to increase organ access. Clin Transplant 2020;34:e13833. [PMID: 32072689 DOI: 10.1111/ctr.13833] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
52 Castaneda D, Gonzalez AJ, Alomari M, Tandon K, Zervos XB. From hepatitis A to E: A critical review of viral hepatitis. World J Gastroenterol 2021; 27(16): 1691-1715 [PMID: 33967551 DOI: 10.3748/wjg.v27.i16.1691] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
53 Said A, Weiss M, Varhelyi A, Farago R, Ballweg C, Rice J, Agarwal P, Fernandez L, Foley D. Utilization of hepatitis C viremic donors for liver transplant recipients without hepatitis C. A veterans transplant center report. Transpl Infect Dis.  2020: e13466. [PMID: 32931616 DOI: 10.1111/tid.13466] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
54 Altshuler PJ, Helmers MR, Schiazza AR, Hu R, Han JJ, Herbst DA, Iyengar A, Atluri P. HCV-Positive Allograft Use in Heart Transplantation Is Associated With Increased Access to Overdose Donors and Reduced Waitlist Mortality Without Compromising Outcomes. J Card Fail 2021:S1071-9164(21)00297-9. [PMID: 34314824 DOI: 10.1016/j.cardfail.2021.07.007] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
55 Sobotka LA, Mumtaz K, Wellner MR, Kelly SG, Conteh LF, Hanje AJ, Schenk A, El-Hinnawi A, Black S, Washburn K, Pesavento T, Daloul R, Michaels AJ. Outcomes of hepatitis C virus seropositive donors to hepatitis C virus seronegative liver recipients: A large single center analysis. Ann Hepatol 2021;24:100318. [PMID: 33515801 DOI: 10.1016/j.aohep.2021.100318] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
56 Fabrizi F, Cerutti R, Silva M. HCV-infected solid organ donors, direct-acting antivirals and the current challenges. Expert Rev Clin Pharmacol 2020;13:7-14. [PMID: 31786966 DOI: 10.1080/17512433.2020.1697677] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
57 Bowring MG, Shaffer AA, Massie AB, Cameron A, Desai N, Sulkowski M, Garonzik-Wang J, Segev DL. Center-level trends in utilization of HCV-exposed donors for HCV-uninfected kidney and liver transplant recipients in the United States. Am J Transplant 2019;19:2329-41. [PMID: 30861279 DOI: 10.1111/ajt.15355] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
58 Lonze BE, Baptiste G, Ali NM, Dagher NN, Gelb BE, Mattoo A, Soomro I, Tatapudi VS, Montgomery RA, Stewart ZA. Pancreas transplantation from hepatitis C viremic donors to uninfected recipients. Am J Transplant 2021;21:1931-6. [PMID: 33346951 DOI: 10.1111/ajt.16465] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
59 Siddiqi HK, Schlendorf KH. Hepatitis C Positive Organ Donation in Heart Transplantation. Curr Transplant Rep 2021;:1-9. [PMID: 34786324 DOI: 10.1007/s40472-021-00350-1] [Reference Citation Analysis]
60 Aslam S, Grossi P, Schlendorf KH, Holm AM, Woolley AE, Blumberg E, Mehra MR; working group members. Utilization of hepatitis C virus-infected organ donors in cardiothoracic transplantation: An ISHLT expert consensus statement. J Heart Lung Transplant 2020;39:418-32. [PMID: 32362393 DOI: 10.1016/j.healun.2020.03.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
61 McLean RC, Reese PP, Acker M, Atluri P, Bermudez C, Goldberg LR, Abt PL, Blumberg EA, Van Deerlin VM, Reddy KR, Bloom RD, Hasz R, Suplee L, Sicilia A, Woodards A, Zahid MN, Bar KJ, Porrett P, Levine MH, Hornsby N, Gentile C, Smith J, Goldberg DS. Transplanting hepatitis C virus-infected hearts into uninfected recipients: A single-arm trial. Am J Transplant 2019;19:2533-42. [PMID: 30768838 DOI: 10.1111/ajt.15311] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 17.0] [Reference Citation Analysis]
62 Burton JR Jr, Terrault NA, Goldberg DS, Bloom RD, Gilroy R, Heimbach JK, Brown RS Jr, Everson GT, Rubin E, Wiesner R, Pomfret EA. Liver and Kidney Recipient Selection of Hepatitis C Virus Viremic Donors: Meeting Consensus Report From the 2019 Controversies in Transplantation. Transplantation 2020;104:476-81. [PMID: 31634329 DOI: 10.1097/TP.0000000000003014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
63 Polanco NP, Goldberg D. Transplanting Livers From "HCV-Positive" Donors To HCV-Negative Recipients: Increased Experience But Many Unanswered Questions. Am J Gastroenterol 2020;115:1022-3. [PMID: 32618651 DOI: 10.14309/ajg.0000000000000649] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
64 Ting PS, Hamilton JP, Gurakar A, Urrunaga NH, Ma M, Glorioso J, King E, Toman LP, Wesson R, Garonzik-Wang J, Ottmann S, Philosophe B, Sulkowski M, Cameron AM, Durand CM, Chen PH. Hepatitis C-positive donor liver transplantation for hepatitis C seronegative recipients. Transpl Infect Dis 2019;21:e13194. [PMID: 31609520 DOI: 10.1111/tid.13194] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
65 Mazur RD, Goldberg DS. Temporal Changes and Regional Variation in Acceptance of Hepatitis C Virus-Viremic Livers. Liver Transpl 2019;25:1800-10. [PMID: 31539195 DOI: 10.1002/lt.25644] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
66 Danford CJ, Redman JS, Alonso D. Hepatitis C-positive liver transplantation: outcomes and current practice. Curr Opin Organ Transplant 2021;26:115-20. [PMID: 33595978 DOI: 10.1097/MOT.0000000000000848] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Kapila N, Menon KN, Al‐khalloufi K, Vanatta JM, Murgas C, Reino D, Ebaid S, Shaw JJ, Agrawal N, Rhazouani S, Navas V, Sheffield C, Rahman AU, Castillo M, Lindenmeyer CC, Miller C, Quintini C, Zervos XB. Hepatitis C Virus NAT‐Positive Solid Organ Allografts Transplanted Into Hepatitis C Virus–Negative Recipients: A Real‐World Experience. Hepatology 2020;72:32-41. [DOI: 10.1002/hep.31011] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 22.5] [Reference Citation Analysis]
68 Tabrizian P, Saberi B, Holzner ML, Rocha C, Kyung Jung Y, Myers B, Florman SS, Schwartz ME. Outcomes of transplantation for HBV- vs. HCV-related HCC: impact of DAA HCV therapy in a national analysis of >20,000 patients. HPB (Oxford) 2021:S1365-182X(21)01723-8. [PMID: 34955348 DOI: 10.1016/j.hpb.2021.11.018] [Reference Citation Analysis]